July 2026 in “Pharmaceuticals” This review examined mechanisms regulating muscle repair, highlighting disruptions in aging and chronic diseases like Duchenne muscular dystrophy and diabetes. It noted that chronic inflammation and metabolic dysfunction hinder effective regeneration and discussed emerging therapies, suggesting multi-target approaches could be promising despite limited clinical evidence.
November 2024 in “Communities in ADDI (University of the Basque Country)” Antisense oligonucleotides show promise for treating Myotonic Dystrophy type I.
1 citations
,
November 2025 in “Clinical and Experimental Medicine” This review highlights the emerging role of long non-coding RNAs (lncRNAs) in dermatology, suggesting that lncRNAs significantly impact signaling pathways involved in normal skin functions and skin diseases, offering potential as biomarkers and therapeutic targets.
17 citations
,
July 2017 in “Molecular and Cellular Endocrinology” The authors reviewed the mechanisms behind Kennedy's disease, noting advances in therapeutic strategies such as androgen deprivation and gene silencing that may soon expand treatment options for this incurable neuromuscular condition.
March 2026 in “Frontiers in Medicine” In this review, recent studies on muscle atrophy are highlighted, revealing insights into its complex pathogenesis, therapeutic interventions such as hormone therapy, and diagnostic advancements, while emphasizing the need for personalized approaches and addressing challenges like small sample sizes and methodological diversity.